Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(20%)
Results Posted
50%(2 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
1
10%
Ph phase_3
1
10%
Ph phase_4
3
30%
Ph early_phase_1
1
10%
Ph phase_2
4
40%

Phase Distribution

2

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Recruiting2
Enrolling by invitation2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (10.0%)
Phase 11 (10.0%)
Phase 24 (40.0%)
Phase 31 (10.0%)
Phase 43 (30.0%)

Trials by Status

recruiting220%
enrolling_by_invitation220%
completed440%
terminated220%

Recent Activity

2 active trials
Showing 5 of 10
recruitingearly_phase_1

Using Aspirin to Improve Immunological Features of Ovarian Tumors

NCT05080946
recruitingphase_3

Trial to Determine Effective Aspirin Dose in COPD

NCT05265299
completedphase_4

Body Weight, Aspirin Dose and Pro-resolving Mediators

NCT04697719
enrolling_by_invitationphase_4

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020
enrolling_by_invitationphase_4

PFA 100 Evaluation and Reference Interval HOACNY

NCT06100510
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05080946Early Phase 1

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Recruiting
NCT05265299Phase 3

Trial to Determine Effective Aspirin Dose in COPD

Recruiting
NCT04697719Phase 4

Body Weight, Aspirin Dose and Pro-resolving Mediators

Completed
NCT03244020Phase 4

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

Enrolling By Invitation
NCT06100510Phase 4

PFA 100 Evaluation and Reference Interval HOACNY

Enrolling By Invitation
NCT03152409Phase 2

Salicylic Augmentation in Depression

Terminated
NCT05166096Phase 1

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects

Completed
NCT04062032Phase 2

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

Completed
NCT04066725Phase 2

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

Completed
NCT00783614Phase 2

Aspirin and Antiretroviral Therapy in HIV Infected Patients

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10